Morgan Stanley’s Calithera Biosciences, Inc CALA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-697
| Closed | -$2.27K | – | 8020 |
|
|
2022
Q4 | $2.27K | Buy |
697
+17
| +3% | +$41 | ﹤0.01% | 7339 |
|
|
2022
Q3 | $2K | Hold |
680
| – | – | ﹤0.01% | 7523 |
|
|
2022
Q2 | $2K | Sell |
680
-385
| -36% | -$1.78K | ﹤0.01% | 7646 |
|
|
2022
Q1 | $9K | Sell |
1,065
-9,687
| -90% | -$99K | ﹤0.01% | 7453 |
|
|
2021
Q4 | $143K | Buy |
10,752
+8,803
| +452% | +$221K | ﹤0.01% | 6247 |
|
|
2021
Q3 | $85K | Sell |
1,949
-47,326
| -96% | -$2.04M | ﹤0.01% | 6468 |
|
|
2021
Q2 | $2.06M | Buy |
49,275
+49,258
| +289,753% | +$2.16M | ﹤0.01% | 4609 |
|
|
2021
Q1 | $1K | Sell |
17
-2,610
| -99% | -$152K | ﹤0.01% | 7442 |
|
|
2020
Q4 | $258K | Buy |
2,627
+2,180
| +488% | +$191K | ﹤0.01% | 5460 |
|
|
2020
Q3 | $30K | Sell |
447
-788
| -64% | -$68.8K | ﹤0.01% | 5912 |
|
|
2020
Q2 | $131K | Buy |
1,235
+861
| +230% | +$102K | ﹤0.01% | 5277 |
|
|
2020
Q1 | $33K | Sell |
374
-2,948
| -89% | -$351K | ﹤0.01% | 5629 |
|
|
2019
Q4 | $380K | Buy |
3,322
+2,409
| +264% | +$181K | ﹤0.01% | 5089 |
|
|
2019
Q3 | $56K | Buy |
913
+793
| +661% | +$63.5K | ﹤0.01% | 5681 |
|
|
2019
Q2 | $10K | Sell |
120
-328
| -73% | -$37.2K | ﹤0.01% | 6145 |
|
|
2019
Q1 | $61K | Sell |
448
-2,047
| -82% | -$215K | ﹤0.01% | 5585 |
|
|
2018
Q4 | $200K | Sell |
2,495
-1,322
| -35% | -$130K | ﹤0.01% | 5287 |
|
|
2018
Q3 | $401K | Buy |
3,817
+427
| +13% | +$40.7K | ﹤0.01% | 5117 |
|
|
2018
Q2 | $339K | Sell |
3,390
-52
| -2% | -$5.89K | ﹤0.01% | 5314 |
|
|
2018
Q1 | $434K | Sell |
3,442
-135
| -4% | -$21.1K | ﹤0.01% | 5087 |
|
|
2017
Q4 | $598K | Buy |
3,577
+564
| +19% | +$144K | ﹤0.01% | 4870 |
|
|
2017
Q3 | $949K | Sell |
3,013
-2,911
| -49% | -$918K | ﹤0.01% | 4465 |
|
|
2017
Q2 | $1.76M | Buy |
5,924
+1,016
| +21% | +$272K | ﹤0.01% | 3911 |
|
|
2017
Q1 | $1.13M | Buy |
4,908
+4,483
| +1,055% | +$774K | ﹤0.01% | 4287 |
|
|
2016
Q4 | $28K | Buy |
425
+202
| +91% | +$12.6K | ﹤0.01% | 5914 |
|
|
2016
Q3 | $14K | Sell |
223
-58
| -21% | -$3.74K | ﹤0.01% | 6031 |
|
|
2016
Q2 | $21K | Sell |
281
-88
| -24% | -$8.81K | ﹤0.01% | 5840 |
|
|
2016
Q1 | $42K | Sell |
369
-111
| -23% | -$12.6K | ﹤0.01% | 5683 |
|
|
2015
Q4 | $74K | Buy |
480
+354
| +281% | +$53.1K | ﹤0.01% | 5561 |
|
|
2015
Q3 | $14K | Buy |
126
+75
| +147% | +$9.72K | ﹤0.01% | 6164 |
|
|
2015
Q2 | $7K | Buy |
51
+36
| +240% | +$8.35K | ﹤0.01% | 6383 |
|
|
2015
Q1 | $5K | Sell |
15
-21
| -58% | -$7.47K | ﹤0.01% | 6348 |
|
|
2014
Q4 | $14K | Buy |
+36
| New | +$9.4K | ﹤0.01% | 6145 |
|
Other funds holding CALA
Morgan Stanley's CALA Position: Q1 2023 in Review
Morgan Stanley sold out of Calithera Biosciences, Inc (CALA) in Q1 2023, closing a stake of 697 shares — an estimated $2.27K sold.
Morgan Stanley first reported a position in CALA in Q4 2014 and held it in 33 quarters. The position peaked at $2.06M in Q2 2021. 2 funds tracked by Wall St. Rank hold CALA as of Q1 2023.
- Morgan Stanley reported no remaining Calithera Biosciences, Inc position as of Q1 2023 after selling out during the quarter.
- Morgan Stanley sold 697 Calithera Biosciences, Inc shares in Q1 2023, an estimated $2.27K.
- Morgan Stanley first reported a position in Calithera Biosciences, Inc in Q4 2014 and held it in 33 quarters.
- Morgan Stanley's Calithera Biosciences, Inc position peaked at $2.06M in Q2 2021.
- 2 funds tracked by Wall St. Rank held Calithera Biosciences, Inc as of Q1 2023.
Based on Morgan Stanley's 13F filing for Q1 2023, filed 15 May 2023.